The Motley Fool
03 Nov 2025, 23:12 UTC · 45w ago
Verdict
Headline leans bullish. We score IDXX +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Idexx Laboratories raised its full-year 2025 guidance for both revenue ($4.27B–$4.3B) and earnings per share ($12.81–$13.01).
So whatRaised guidance signals management's confidence in future growth and typically triggers a sustained positive re-rating of the stock.
More positive than 98% of claims this week
Idexx reported third-quarter revenue of $1.11 billion and adjusted EPS of $3.22, both exceeding analyst consensus estimates.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 92% of claims this week
GAAP net income for the quarter grew by 18% to $274.6 million, while revenue increased 13% year-over-year.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported quarterly revenue and net income that beat analyst estimates and raised its full-year guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3d ago
−29.2%
Price is moving against the score
$511.65 vs $722.94 close before publication (Nov 3) · not market-adjusted
IDXX chart →
